C. McCarthy (Dublin 4, Ireland), M. Molina Molina (Barcelona, Spain)
Incidence and prevalence of Systemic Sclerosis-associated Interstitial Lung Disease in a multicenter prospective cohort study.
E. Vandecasteele (Ghent, Belgium), K. Melsens (Ghent, Belgium), D. Blockmans (Leuven, Belgium), C. Carton (Ghent, Belgium), F. De Keyser (Ghent, Belgium), E. De Langhe (Leuven, Belgium), B. Lauwerys (Brussels, Belgium), Y. Piette (Ghent, Belgium), A. Vanhaecke (Ghent, Belgium), K. Verbeke (Ghent, Belgium), W. Wuyts (Leuven, Belgium), G. Brusselle (Ghent, Belgium), V. Smith (Ghent, Belgium)
|   |
Effects of nintedanib in patients with SSc-ILD and preserved and highly impaired lung function
W. Wuyts (Leuven, Belgium), A. Azuma (Tokyo, Japan), J. Distler (Erlangen, Germany), K. Sondergaard (Aarhus, Denmark), S. Proudman (Adelaide, Australia), V. Cottin (Lyon, France), E. Erhardt (Sulzbach, Germany), M. Quaresma (Ingelheim am Rhein, Germany), M. Gahlemann (Basel, Switzerland), M. Alves (Ingelheim am Rhein, Germany), T. Maher (London, United Kingdom)
| |
FVC decline in patients with SSc-ILD by use of anti-acid therapy
M. Kreuter (Heidelberg, Germany), H. Nunes (Bobigny, France), G. Criner (Philadelphia, Pennsylvania, United States of America), P. Sfikakis (Athens, Greece), W. Stevens (Melbourne, Victoria, Australia), C. Miede (Weimar (Lahn), Germany), M. Quaresma (Ingelheim, Germany), M. Alves (Ingelheim, Germany), G. Raghu (Seattle, Washington, United States of America)
| |
Rerationship between interstitial pneumonia related systemic sclerosis and esophageal motility abnormalities
K. HARA (Maebashi, Gunma, Japan), K. Yamaguchi (Maebashi, Gunma, Japan), M. Yatomi (Maebashi, Gunma, Japan), H. Tsurumaki (Maebashi, Gunma, Japan), T. Hisada (Maebashi, Gunma, Japan), T. Maeno (Maebashi, Gunma, Japan)
| |
Interstitial lung disease with ANCA-associated vasculitis (AAV-ILD): Clinical features and survival compared to patients with ILD associated with systemic sclerosis and IPF
F. Reyes (Santiago , Chile), S. Saavedra (Santiago , Chile), K. Vergara (Santiago , Chile), P. Wurmann (Santiago , Chile)
| |
Lung involvement in primary biliary cholangitis (PBC)
V. Sholomova (Moscow, Russian Federation), L. Akulkina (Moscow, Russian Federation), M. Brovko (Moscow, Russian Federation), M. Kalashnikov (Moscow, Russian Federation), D. Konovalov (Moscow, Russian Federation), A. Yanakaeva (Moscow, Russian Federation), S. Moiseev (Moscow, Russian Federation)
| |
Effect of anti-IL-17 biologics on KL-6 level and coexisting interstitial pneumoniain patients with psoriasis
H. Hara (Tokyo, Japan), H. Miyagawa (Tokyo, Japan), J. Araya (Tokyo, Japan), S. Minagawa (Tokyo, Japan), T. Numata (Tokyo, Japan), Y. Umezawa (Tokyo, Japan), A. Asahina (Tokyo, Japan), K. Kuwano (Tokyo, Japan)
| |
Clinical characteristics of lymphangioleiomyomatosis and application of a novel automated cyst burden score
E. Lynn (Dublin, Ireland), J. Morrow (DublinBlackrock (Co. Dublin), Ireland), A. Kelly (DublinDublinBlackrock (Co. Dublin), Ireland), A. Fabre (DublinDublinBlackrock (Co. Dublin), Ireland), J. Dodd (DublinDublinBlackrock (Co. Dublin), Ireland), M. Keane (DublinDublinBlackrock (Co. Dublin), Ireland), D. Murphy (DublinDublinBlackrock (Co. Dublin), Ireland), C. Mccarthy (DubliDublinDnDublinBlackrock (Co. Dublin), Ireland)
| |
Comparison of pulmonary function tests (PFTs) and 6-minute walk test (6MWT) in patients with lymphangioleiomyomatosis (LAM)
R. Diesler (Bron, France), V. Cottin (Bron, France), S. Turquier (Bron, France), M. Nasser (Bron, France), K. Ahmad (Bron, France), J. Traclet (Bron, France), J. Glerant (Bron, France)
| |
Design of phase II, randomized, placebo-controlled study of loratadine associate with rapamycin in patients with lymphangioleiomyomatosis (LAM)
J. Bordas-Martínez (Barcelona, Spain), C. Herranz (Barcelona, Spain), V. Vicens-Zygmunt (Barcelona, Spain), A. Román (Barcelona, Spain), C. Berastegui (Barcelona, Spain), P. Ussetti (Madrid, Spain), R. Laporta (Madrid, Spain), J. Ancochea (Madrid, Spain), C. Valenzuela (Madrid, Spain), A. Casanova (Madrid, Spain), E. Ansótegui (Valencia, Spain), J. Rodríguez-Portal (Sevilla, Spain), G. Bermudo (Barcelona, Spain), P. Luburich (Barcelona, Spain), R. Llatjós (Barcelona, Spain), S. Santos (Barcelona, Spain), J. Dorca (Barcelona, Spain), P. Hereu (Barcelona, Spain), M. Pujana * Sharing Senior Position (Barcelona, Spain), M. Molina-Molina * Sharing Senior Position (Barcelona, Spain)
| |
Birt Hogg-Dubé syndrome in Poland
E. Radzikowska (Warszawa, Poland), L. Opoka (Warszawa, Poland), J. Winek (Warszawa, Poland), K. Blasinska (Warszawa, Poland), E. Wiatr (Warszawa, Poland)
| |
Pivotal role of the HMGB1/sRAGE axis in drug-induced lung injury in advanced lung cancer with pre-existing interstitial lung disease
S. Nakao (hiroshima, Japan), Y. Kakuhiro (hiroshima, Japan), S. Sakamoto (hiroshima, Japan), Y. Horimasu (hiroshima, Japan), T. Masuda (hiroshima, Japan), S. Miyamoto (hiroshima, Japan), T. Nakashima (hiroshima, Japan), H. Iwamoto (hiroshima, Japan), S. Ohshimo (hiroshima, Japan), K. Fujitaka (hiroshima, Japan), H. Hamada (hiroshima, Japan), N. Hattori (hiroshima, Japan)
| |
Clinical characteristics of a Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) Cohort
M. Gleeson (Dublin, Ireland), A. Fabre (Dublin, Ireland), D. O' Toole (Dublin, Ireland), R. Crowley (Dublin, Ireland), D. Murphy (Dublin, Ireland), C. Mc Carthy (Dublin, Ireland)
| |
Effectiveness of chemotherapy treatment for patients with pulmonary Langerhans cell histiocytosis during long-term follow-up
A. Zinchenko (St. Petersburg, Russian Federation), L. Novikova (St. Petersburg, Russian Federation), M. Ilkovich (St. Petersburg, Russian Federation)
| |
Mini-whole lung lavage to treat pulmonary alveolar proteinosis (PAP)
E. Salvaterra (Pavia, Italy), S. Lettieri (Pavia, Italy), F. Mariani (Pavia, Italy), D. Piloni (Pavia, Italy), F. Meloni (Pavia, Italy), I. Campo (Pavia, Italy)
| |
Novel method of whole lung lavage therapy using biphasic cuirass ventilator for pulmonary alveolar proteinosis; the retrospective observational study.
d. tamanoi (kumamoto-shi, Japan), C. Yoshida (kumamoto-shi, Japan), T. Kimura (kumamoto-shi, Japan), T. Jodai (kumamoto-shi, Japan), T. Isimura (kumamoto-shi, Japan), S. Okamoto (kumamoto-shi, Japan), H. Ichiyasu (kumamoto-shi, Japan), T. Yamamoto (kumamoto-shi, Japan), T. Sakagami (kumamoto-shi, Japan)
| |
A single-centre retrospective study to phenotype unclassifiable interstitial lung disease
L. Fabbri (Modena , Italy), M. Nasser (Lyon, France), K. Ahmad (Lyon, France), J. Traclet (Lyon, France), V. Cottin (Lyon, France)
| |
Comorbidities in unclassifiable interstitial lung disease
C. Hyldgaard (Silkeborg, Denmark), S. Torrisi (Catania, Italy), S. Kronborg-White (Aarhus, Denmark), C. Ganter (Heidelberg, Germany), E. Bendstrup (Aarhus, Denmark), M. Kreuter (Heidelberg, Germany)
| |